Total revenues of the Merck Group increased 3.8% to € 2,532 million in the third quarter from € 2,438 million in the year-ago quarter with solid contributions from the Pharmaceuticals divisions and the Merck Millipore life science division. Exchange rate movements reduced third-quarter revenue growth by 2.2% and divestments subtracted a further 0.9%. Adjusted for these items, third quarter organic revenue growth was 6.9%.
Royalty, license and commission income rose 7.2% to € 97 million in the third quarter. The Group’s third-quarter gross margin was € 1,852 million, or 73% of total revenues, compared to € 1,818 million, or 75% of total revenues, in the third quarter of 2010. The percentage decline was the result of negative currency effects, unfavorable product mixes and higher production costs.
|
Components of growth by division – Q3 |
|||||
|
|
|
|
|
|
|
|
Change in total revenues |
Merck Serono |
Consumer Health Care |
Merck Millipore |
Performance Materials |
Merck Group |
|
Organic growth |
8.9 |
7.1 |
7.3 |
–1.3 |
6.9 |
|
Currency effects |
–1.9 |
–0.8 |
–3.5 |
–1.7 |
–2.2 |
|
Acquisitions/divestments |
–1.5 |
– |
1.5 |
–2.2 |
–0.9 |
|
Total |
5.4 |
6.3 |
5.2 |
–5.2 |
3.8 |
back
